- Home
- EQX vs PTGX Comparison
EQX vs PTGX Comparison
Compare EQX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- PTGX
- Stock Information
- Founded
- EQX 2007
- PTGX 2006
- Country
- EQX Canada
- PTGX United States
- Employees
- EQX N/A
- PTGX N/A
- Industry
- EQX Precious Metals
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- PTGX Health Care
- Exchange
- EQX Nasdaq
- PTGX Nasdaq
- Market Cap
- EQX 2.7B
- PTGX 2.3B
- IPO Year
- EQX N/A
- PTGX 2016
- Fundamental
- Price
- EQX $6.82
- PTGX $38.75
- Analyst Decision
- EQX
- PTGX Strong Buy
- Analyst Count
- EQX 0
- PTGX 8
- Target Price
- EQX N/A
- PTGX $57.13
- AVG Volume (30 Days)
- EQX 8.2M
- PTGX 528.6K
- Earning Date
- EQX 02-19-2025
- PTGX 02-21-2025
- Dividend Yield
- EQX N/A
- PTGX N/A
- EPS Growth
- EQX 733.33
- PTGX N/A
- EPS
- EQX 0.75
- PTGX 4.23
- Revenue
- EQX $1,514,120,000.00
- PTGX $434,433,000.00
- Revenue This Year
- EQX $47.03
- PTGX $445.33
- Revenue Next Year
- EQX $52.06
- PTGX N/A
- P/E Ratio
- EQX $9.15
- PTGX $9.16
- Revenue Growth
- EQX 39.14
- PTGX 624.05
- 52 Week Low
- EQX $3.95
- PTGX $24.22
- 52 Week High
- EQX $7.22
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- EQX 57.65
- PTGX 52.47
- Support Level
- EQX $6.38
- PTGX $37.50
- Resistance Level
- EQX $7.22
- PTGX $39.37
- Average True Range (ATR)
- EQX 0.31
- PTGX 1.32
- MACD
- EQX 0.00
- PTGX 0.16
- Stochastic Oscillator
- EQX 65.52
- PTGX 67.70
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing pipeline of growth projects.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.